

Confirmed Speakers

Plenary Lectures

Medicinal Chemistry Experts in Pharma are Helping us to Generate Freely Available Novel Probes in Order to Facilitate Target Discovery




Prof. Chas BOUNTRA
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

IUPAC Richter Prize Lecture Medicinal Chemistry, Quo Vadis? - The Changing Climate In R&D



Dr Helmut BUSCHMANN
(PHARMA CONSULTING AACHEN, Aachen, Germany)

The UCB-Ehrlich Award for Excellence in Medicinal Chemistry Small Molecule Control Of Intracellular Protein Levels



Prof. Craig CREWS
(YALE UNIVERSITY, New Haven, United States)

Portugal: the Right Place to build Partnerships in Health



Dr Joaquim CUNHA
(HEALTH CLUSTER PORTUGAL, Maia, Portugal)

The Prous Institute-Overton and Meyer Award for New Technologies i Drug Discovery Thermodynamics Assisted Drug Discovery



Dr György G. FERENCZY
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)



Prof. Gyorgy KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

Plenary Lecture



Dr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)

The Nauta Award for Pharmacochemistry Pursuing Compound Quality



Dr Paul LEESON
(GLAXOSMITHKLINE, United Kingdom)

High Resolution Mass Spectrometry in Clinical Proteomics

Confirmed Speakers



Prof. Dr Matthias MANN
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany)

Innovation Through Chemistry at the Interfaces of the Scientific Disciplines

Dr Martin MISSBACH
(NOVARTIS, Basel, Switzerland)

Partnership between Public and Private Sources: Pharma and IMI Perspective



Dr Paul Peter TAK
(EFPIA, Brentford, United Kingdom)

Plenary Lecture



Prof. Hans WESTERHOFF
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Invited Speakers

Targeting Spore Germination to Prevent Clostridium Difficile Infections



Dr Ernesto ABEL-SANTOS
(UNIVERSITY OF NEVADA, LAS VEGAS, Nevada, Las Vegas, United States)

Cyclic Peptides from the nature to the synthetic ones



Prof. Fernando ALBERICIO
(UNIVERSITY OF BARCELONA, Barcelona, Spain)

Sponging Off Nature for New Drug Leads



Prof. Raymond ANDERSEN
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)

Omarigliptin: A Once-weekly Oral Antidiabetic Agent



Dr Tesfaye BIFTU
(MERCK, Rahway, United States)

Design, Synthesis and Development of Lysophosphatidic Acid Receptor 1 (LPA1) PET Radioligands for Lung Receptor Occupancy Imaging



Dr Sam BONACORSI
(BRISTOL-MYERS SQUIBB, Princeton, United States)

Invited Lecture

Confirmed Speakers



Dr Terry BOWLIN
(MICROBIOTIX, Worcester, United States)

Being More Certain About Uncertainty In Computational Toxicology Modeling



Dr Scott BOYER
(KAROLINSKA INSTITUTET, Södertälje, Sweden)

Update on Chemotherapy of Tropical Diseases Caused by Protozoan Parasites



Prof. Reto BRUN
(SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE, Basel, Switzerland)

Recent Advances In Asymmetric Catalysis



Prof. Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland)

Inflammation, Obesity and Metabolic Disease



Dr Ajay CHAWLA
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

Efficient Determination Of Protein-Ligand Standard Binding Free Energies And Permeabilities With A Computational Microcalorimeter



Dr Chris CHIPOT
(UNIVERSITY OF ILLINOIS, Urbana, United States)

Binding Affinity Prediction from Molecular Simulation – Soon a Standard Method in Structure-Based Drug Design?



Dr Clara CHRIST
(BAYER PHARMA, Berlin, Germany)

Functional and Structural Insights into GPCR Allostery



Prof. Arthur CHRISTOPOULOS
(MONASH UNIVERSITY, Parkville, Australia)

BETting on Bromodomains: Developing Inhibitors of the Bromodomain-Acetyl-Lysine Interaction



Prof. Stuart CONWAY
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

New Stereoselective Organocatalytic Reactions for the Synthesis of Isoquinoline Alkaloids

Confirmed Speakers



Prof. Pier Giorgio COZZI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

Exploring the Dynamics of Ligand-Protein Interactions using SPR Biosensors



Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)

Breaking The Equilibrium Dissociation Constant Into Fragments: The Use Of Binding Kinetics And Thermodynamics In The Development Of Selective Ligands.



Prof. Iwan DE ESCH
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Exploiting Tumor Metabolic Vulnerabilities with Novel OxPhos Inhibitors



Dr Maria Emilia DI FRANCESCO
(UTMD ANDERSON CANCER CENTER, Houston, United States)

Visualising Novel Macrolide Antibiotics Bound to Their Ribosomal Target



Prof. Stephen DOUTHWAITE
(UNIVERSITY OF SOUTHERN DENMARK, Odensen, Denmark)

A Rational Approach to the Development of Radioligands and PET Ligands for Drug Development



Dr Chad ELMORE
(ASTRAZENECA PHARMACEUTICALS, Mölndal, Sweden)

Epigenetic Drug Discovery: Small Molecule Inhibitors of Class IV Bromodomain Proteins



Prof. Paul FISH
(UCL SCHOOL OF PHARMACY, London, United Kingdom)

Experiences with Natural Product Total Synthesis



Prof. Alois FÜRSTNER
(MAX PLANCK INSTITUT FÜR KOHLENFORSCHUNG, Muelheim an der Ruhr, Germany)

Antimalarial Lead Discovery from phenotypic screening: Unraveling the Black Box



Dr Francisco-Javier GAMO
(GLAXOSMITHKLINE, Madrid, Spain)

CNV1014802, a Novel Nav1.7 Selective State-Dependent Sodium Channel Blocker for the Treatment of Chronic Pain: From Discovery to Phase 2 Clinical Study

Confirmed Speakers



Dr Gerard GIBLIN
(CONVERGENCE PHARMACEUTICALS, Cambridge, United Kingdom)

Mechanism-Based Prediction of Drug-Induced Liver Injury



Dr Christopher GOLDRING
(UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom)

Integration of New Chemical Diversity and Design Approaches in Lead Generation



Dr Timothy GRESE
(ELI LILLY AND COMPANY, Indianapolis, United States)

CB2 Agonists Protect from Inflammation Related Kidney Damage and Fibrosis



Dr Uwe GREThER
(F. HOFFMANN-LA-ROCHE, Basel, Switzerland)

Mechanoenzymatics of Biomolecular Machines: Free Energies, Dynamics, Function



Prof. Helmut GRUBMÜLLER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

An Introduction To Ion Channels As Drug Targets



Prof. Morten GRUNNET
(LUNDBECK, Valby, Denmark)

MedChemComm Prize Winner : Phage Selection Of Bicyclic Peptides For Therapeutic Application



Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

Discovery of the mGlu5 Negative Allosteric Modulator RO4917523



Dr Georg JAESCHKE
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Development of New Anti-Infective Agents and a Novel Delivery Strategy



Prof. Reuben JIH-RU HWU
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)

Synthesis of Anti-infective Cyclic Natural Products and Natural Product-like Compounds

Confirmed Speakers



Prof. Han-Young KANG
(CHUNGBUK NATIONAL UNIVERSITY, Cheongju, Korea, South)

Bioactive Secondary Metabolites From The Soil And Marine-Derived Fungi Of The Genus Neosartorya



Prof. Anake KIJOA
(UNIVERSITY OF PORTO, Porto, Portugal)

Pharmaceutical Protein & Peptide Engineering: From Once Daily To Once Weekly GLP-1 Dosing



Dr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)

Translational Modeling in Support to Discovery and Early Development



Dr Thierry LAVE
(F.HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

Pain-relieving Peptides Targeting Acid-Sensing Ion Channels



Dr Eric LINGUEGLIA
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)

Novel Anti-Cancer Treatment Targeting Vps34



Dr Jessica MARTINSSON
(SPRINT BIOSCIENCE, Stockholm, Sweden)

High End Design for GPCRs: Combining Protein Structure, Biophysical Data and Computational Water Network Energies



Dr. Jonathan MASON
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)

Non-Clinical Characterization And Clinical Translation Of LY2811376 And LY2886721



Dr Dustin James MERGOTT
(ELI LILLY, Indianapolis, United States)

The Impact of Polypharmacology on Lead Generation



Prof. Jordi MESTRES
(IMIM AND UNIVERSITY POMPEU FABRA, Barcelona, Spain)

Therapeutic Opportunities Offered by the Excessive Lactate Production in Cancer

Confirmed Speakers



Prof. Filippo MINUTOLO
(UNIVERSITY OF PISA, Pisa, Italy)

Metalation of Polyfunctional Heterocyclic Compounds: Applications in Agrochemistry



Dr Marc MOSRIN
(BAYER CROPSCIENCE AG, Frankfurt am Main, Germany)

Successful Drug Discovery And Development Case Studies Of Protein Epitope Mimetics



Dr Daniel OBRECHT
(POLYPHOR, Allschwil, Switzerland)

A First In Class Chemical Probe For Family VIII Bromodomains



Dr Dafydd OWEN
(PFIZER, Cambridge, United States)

Novel Boron-containing Anti-infective Agents



Dr Jacob PLATTNER
(ANACOR PHARMACEUTICALS, Palo Alto, United States)

Restoration of Muscle Mass and Lifespan in a Mouse Model of Spinal Muscular Atrophy by Molecular Correction of SMN2 Splicing Defect



Dr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

Antimalarial Trioxolanes - Exploiting Peroxide Reduction For Parasite-Selective Drug Delivery



Dr Adam RENSLO
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

Natural Products as Driving Force for Innovation in Pharmaceutical Research and Development



Dr Esther SCHMITT
(NOVARTIS, Basel, Switzerland)

PET Imaging: Synthesis of Radiopharmaceuticals and their Application in Personalized Medicine and Drug Discovery



Dr Peter J.H. SCOTT
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

Confirmed Speakers

The Ribosome as a Drug Target: Insights from Structural Investigations - Towards Rational Drug Design



Dr Moran SHALEV BEN AMI
(WEIZMANN INSTITUTE, Rehovot, Israel)

New Synthetic Routes of Nitrogen and Oxygen Heterocycles and Related Compounds



Prof. Artur M.S. SILVA
(UNIVERSITY OF AVEIRO, Aveiro, Portugal)

Discovery and Development of Surotomycin for the Treatment of C. difficile



Dr Jared SILVERMAN
(CUBIST PHARMACEUTICALS, Lexington, United States)

CaV1.3-Selective L-Type Calcium Channel Negative Allosteric Modulators. Novel Therapeutics to Slow the Progression of Parkinson's Disease



Prof. Rick SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, United States)

Fragment-Based Discovery of BACE Inhibitors for Alzheimer's Disease



Dr Andrew STAMFORD
(MERCK RESEARCH LABORATORIES, Rahway, United States)

Nanobody-Enabled Fragment Screening On Active-State Constrained GPCRs



Prof. Jan STEYAERT
(VUB, Brussels, Belgium)

1,1'-Spiro-Substituted Hexahydrofuroquinoline Derivatives As Potent And Polar Cholesteryl Ester Transfer Protein (CETP) Inhibitors



Dr Thomas TRIESELMANN
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)

Strategies to Identify and Manage the Risks of Chemically Reactive Drug Metabolites



Prof. Nico VERMEULEN
(VU UNIVERSITY, Amsterdam, The Netherlands)

Cell-Permeable Peptide Therapeutics to Effectively Access Intracellular Targets in Cancer Stem Cells

Dr Jörg VOLLMER
(NEXIGEN, Cologne, Germany)

Medicinal Chemistry Optimisation Of Binding Kinetics

Confirmed Speakers



Prof. Mike WARING
(ASTRAZENECA, Newcastle upon Tyne, United Kingdom)

Fast and Safe Synthesis of Pharmaceutically Relevant Molecules



Prof. Thomas WIRTH
(UNIVERSITY OF CARDIFF, Cardiff, United Kingdom)

Starting Small, Thinking Big: The Application of Fragment Based Drug Discovery to Lead Generation



Dr Steve WOODHEAD
(TAKEDA CALIFORNIA, San Diego, United States)

Oral Communications

Lectins as Targets in Antiadhesion Therapy - Example of DC-SIGN And FimH Antagonists



Assoc. Prof. Marko ANDERLUH
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

Covalent Modification of Histones by Nevirapine - A Plausible Pathway to Nevirapine-Induced Cancers?



Dr Alexandra ANTUNES
(INSTITUTO SUPERIOR TÉCNICO, Lisbon, Portugal)

Interrogation the Bromodomain Family through Chemical Biology



Dr Steve BELLON
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

A HTS Assay Predicting Both Passive Intestinal Absorption and Affinity Constant Towards Human Serum Albumin in a Two End-Point Measurement

Mr Alban BUJARD
(UNIVERSITY OF GENEVA, Geneva, Switzerland)

The Discovery of AZD5069; a CXCR2 Antagonist In Phase II Clinical Trials for the Treatment of Asthma



Dr Rhona COX
(ASTRAZENECA, Mölndal, Sweden)

CHF-6001, an Inhaled PDE4 Inhibitor for Asthma and COPD: Synthesis, In Vitro and In Vivo Characterization



Dr Maurizio DELCANALE
(CHIESI, Parma, Italy)

Confirmed Speakers

Structure-Guided Design of Potent, Selective, Orally Bioavailable Tankyrase Inhibitors



Dr Erin DIMAURO
(AMGEN, Cambridge, United States)

Antagonists of the Pseudomonas Quinolone Signal Receptor (PQSR) as Promising Anti-Virulence Agents



Dr Martin EMPTING
(HELMHOLTZ-INSTITUTE F. PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany)

P-Glycoprotein/Membrane Role on Multidrug Resistance: Insights from In Silico Studies



Mr Ricardo FERREIRA
(FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisbon, Portugal)

Covalent Agonists Facilitating Crystallisation of GPCRs



Prof. Peter GMEINER
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)

CRTH2: Can Residence Time Help?



Dr Elena GOMEZ
(ALMIRALL, BARCELONA, Spain)

Discovery of Ivacaftor (Vx-770), a Cfr Potentiator for the Treatment of Cystic Fibrosis in G551d Patients



Dr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)

Discovery of the First and Only Small Molecule II-17 Blockers



Dr Nils HANSEN
(VIPERGEN, Copenhagen, Denmark)

Discovery of TD-5959 (Batefenterol/GSK-961081): A First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and Beta-2 Agonist (MABA) for the Treatment of COPD



Dr Adam HUGHES
(THERAVANCE INC., South San Francisco, United States)

The Discovery of APD334, a Selective S1P1 Functional Antagonist

Confirmed Speakers



Dr Robert JONES
(ARENA PHARM, SAN DIEGO, United States)

Quantitative Imaging of Mglu5 Allosteric Binding Site and its Occupancy by Positron Emission Tomography with The Novel Fluorine-18 Labelled Probe [18f]Pss232



Dr Stefanie KRAMER
(ETH ZÜRICH, Zürich, Switzerland)

Biomarkers after Bacteriochlorin Based Photodynamic Therapy against Cancer



Dr Martyna KRZYKAWSKA-SERDA
(FACULTY OF BIOCHEMISTRY, BIOPHYSICS AND BIOTECHNOLOGY, JAGIELLONIAN UNIVERSITY, Krakow, Poland)

Design, Synthesis and Biological Evaluation of Potent and Selective Class IIA Histone Deacetylase Inhibitors as a Potential Therapy for Huntington's Disease



Dr Christopher LUCKHURST
(BIOFOCUS, Saffron Walden, United Kingdom)

Allosteric Protein Kinases Inhibitors for Neurodegenerative Diseases Therapies



Prof. Ana MARTINEZ
(INSTITUTO DE QUIMICA MEDICA-CSIC, Madrid, Spain)

Discovery and Characterization of A-366, a Novel, Potent and Highly Selective Inhibitor of Histone Methyltransferase G9a



Dr Michael MICHAELIDES
(ABBVIE, North Chicago, United States)

Metal Assisted Synthetic Approaches to Heterocyclic Small Molecules for the Treatment of Cardiovascular Diseases



Prof. Marko D. MIHOVILOVIC
(VIENNA UNIVERSITY OF TECHNOLOGY, Vienna, Austria)

Development of Novel Building Blocks to Accelerate Drug Discovery



Dr Pavel MYKHAILIUK
(ENAMINE, Kyiv, Ukraine)

Discovery of Small Molecule Ror γ Modulators for the Treatment of Autoimmune Diseases

Confirmed Speakers



Dr Frank NARJES
(ASTRAZENECA, Mölndal, Sweden)

Discovery of GPR103 Ligands Demonstrating the Anorexigenic Effect in vivo of GPR103 Antagonism



Dr Anneli NORDQVIST
(ASTRAZENECA, Mölndal, Sweden)

The Evolution of an in vivo Efficacious Bace1 Inhibitor



Dr Daniel OEHLRICH
(JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, Beerse, Belgium)

EFMC Prize for a Young Medicinal Chemist in Academia Inhibitors and Substrates of the Human Lysine Deacylase Enzymes



Prof. Christian A. OLSEN
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

Cadazolid: A New Antibiotic in Development for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)



Dr Philippe PANCHAUD
(ACTELION PHARMACEUTICALS LTD, Allschwil, Switzerland)

EFMC Prize for a Young Medicinal Chemist in Industry Design, Synthesis and Properties of Potent Inhibitors of Pseudomonas Aeruginosa Deacetylase LpxC



Dr Grazia PIZZI
(NOVARTIS PHARMA, Basel, Switzerland)

Identifying Selective Inhibitors of FGFR4 Kinase



Dr Kurt PIKE
(ASTRAZENECA, Cambridge, United Kingdom)

Crystallographic Structures Enable the Discovery of Selective 5-Ht1b Receptor Ligands through Virtual Screening



Dr David RODRIGUEZ DIAZ
(STOCKHOLM UNIVERSITY, Solna, Sweden)

From Malaysian Biodiversity to the Total Synthesis of Dual Inhibitors of BCL-XL and MCL-1 Anti-Apoptotic Protein

Confirmed Speakers



Dr Fanny ROUSSE
(ICSN - CNRS, Gif sur Yvette, France)

Discovery of BAY 1002670 - A Highly Potent and Selective Progesterone Receptor Modulator for Gynecological Therapies



Dr Wolfgang SCHWEDE
(BAYER, Berlin, Germany)

Cebranopadol, a Novel, Potent Analgesic



Dr Henning STEINHAGEN
(GRÜNENTHAL, Verona, Italy)

Novel Potent Inhibitors of the Histone Demethylase KDM1A



Dr Paola VIANELLO
(EUROPEAN INSTITUTE OF ONCOLOGY, Milan, Italy)

Discovery of BAY 85-8501, a Novel and Highly Potent Induced-Fit Binder of Human Neutrophil Elastase for Pulmonary Diseases



Dr Franz VON NUSSBAUM
(BAYER PHARMA, Lyon, France)

Antibodies as Tools to Enable Small Molecule Drug Discovery



Dr Marta WESTWOOD
(UCB, Slough, United Kingdom)

Improving Physicochemical Properties of a Lapatinib-Based Lead Compound that Targets Trypanosoma Brucei



Prof. Jennifer WOODRING
(NORTHEASTERN UNIVERSITY, Boston, United States)

Novel Inhibitors of Alzheimer's Associated Beta-Secretase-Clusters of Heparan Sulfate



Dr Olga ZUBKOVA
(VICTORIA UNIVERSITY OF WELLINGTON, Lower Hutt, New Zealand)